Biosystems International SAS, of Paris, closed a $2.7 million round of funding, which the firm plans to use to complete the development of its blood test for the detecting lung cancer
The company has entered a collaboration with a team of cancer immunologists at Cardiff University, UK, to evaluate TroVax in a Phase I/II study in the lung cancer mesothelioma
Data published in Cancer Research showed that systemically delivered miR-34a molecules reduced the expression of multiple miR-34a targets, induced apoptosis and inhibited growth of established tumors in mouse models of non-small-cell lung cancer
Radient Pharmaceuticals Corp., of Tustin, Calif., said Jaiva Technologies Inc., also of Tustin, plans to submit a clinical trial application to Indian regulators for Phase II trials of Radient's Combination Immunogene Therapy (CIT) technology as a vaccine therapy in non-small-lung cancer
The researchers demonstrated in an animal model of human lung cancer that suppressing BIII-tubulin, a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small-cell lung cancer, using Benitec's technology of DNA-directed RNAi significantly increased the sensitivity of the cancer to standard chemotherapy drugs, including DNA-damaging agents
The researchers demonstrated in an animal model of human lung cancer that suppressing BIII-tubulin, a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small-cell lung cancer, using Benitec's technology of DNA-directed RNAi significantly increased the sensitivity of the cancer to standard chemotherapy drugs, including DNA-damaging agents
Genzyme Genetics, a unit of Genzyme Corp., of Cambridge, Mass., has entered a license agreement with the Moffitt Cancer Center relating to discovery of the combined relationship of two genes - RRM1 and TS - to patient response to non-small-cell lung cancer
Transgene is developing cancer vaccine TG4010, which is set to start Phase IIb/III testing in non-small-cell lung cancer patients by the end of this year
AVEO Pharmaceuticals Inc., of Cambridge, Mass., said it has initiated a Phase II trial evaluating SCH 900105 (AV-299) for the treatment of non-small-cell lung cancer, which triggered an $8.5 million milestone payment by Merck & Co
The combined company, which will be named Pacific Orient BioPharma Group, intends to be an innovative high-tech enterprise engaging in branded generic drug development, market promotion and distribution in China and other emerging markets...to commercialize Oleptro, a once-daily formulation of the antidepressant trazodone, which was approved by the FDA on Feb. 3...The subscription price corresponds to a discount of about 42 percent to the theoretical ex-rights price of SEK106.20 based on the closing
OSI Pharmaceuticals Inc., of Melville, N.Y., said its partner Roche AG, of Basel, Switzerland, received approval from the European Commission for Tarceva (erlotinib) as a monotherapy maintenance treatment in patients with advanced non-small-cell lung cancer (NSCLC) whose disease remains stable after platinum-based initial chemotherapy...The study's authors identified a set of microRNAs that is expressed differentially between primary or metastatic cancers using microRNA microarray data generated
Geron plans to start Phase II testing of imetelstat this year in non-small-cell lung cancer, breast cancer, multiple myeloma and essential thrombocythemia
The firm noted that bavituximab in combination with chemotherapy is in ongoing Phase II trials for the treatment of advanced breast cancer and non-small-cell lung cancer
Ark Therapeutics Group plc, of London, said the first of its small-molecule neuropilin 1 antagonists, EG01257, successfully completed a proof-of-principle study in a preclinical model of lung cancer
Ark Therapeutics Group plc, of London, said the first of its small-molecule neuropilin 1 antagonists, EG01257, successfully completed a proof-of-principle study in a preclinical model of lung cancer
BioWorld International | Wednesday, April 14, 2010
ANX-530 is an emulsion of the chemotherapy drug vinorelbine, and Adventrx is seeking approval for non-small-cell lung cancer. (See BioWorld Today, March 2, 2010
The decision comes after a detailed analysis of primary and updated data from the Phase III study of picoplatin in small-cell lung cancer (SCLC) and an evaluation of the ongoing new drug application process with the FDA...The company will focus its resources on developing pivotal clinical strategies for picoplatin in small-cell lung cancer, as well as colorectal, prostate and ovarian cancers. (See BioWorld Today, Nov. 17, 2009
Biosystems International SAS, of Paris, closed a $2.7 million round of funding, which the firm plans to use to complete the development of its blood test for the detecting lung cancer